Mesothelioma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Conditions:   Mesothelioma;   Malignant Mesothelioma (MM);   Early-stage Mesothelioma;   Subclinical Mesothelioma;   BRCA1-Associated Protein-1 (BAP1) Mutations;   Early-stage BAP1-associated Malignancies Intervention:   Drug: Decitabine/cedazuridine Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

HTL0039732 in Participants With Advanced Solid Tumours
Conditions:   Neoplasms;   Prostatic Neoplasms, Castration-Resistant;   Stomach Neoplasms;   Esophageal Neoplasms;   Head and Neck Neoplasms;   Colorectal Neoplasms;   Pancreatic Neoplasms;   Lung Neoplasms;   Urinary Bladder Neoplasms;   Mesothelioma, Malignant;   Uterine Cervical Ne oplasms;   Kidney Neoplasms;   Sarcoma;   Pheochromocytomas Interventions:   Drug: HTL0039732 Capsules;   Drug: HTL0039732 Capsules and atezolizumab infusion Sponsors:   Cancer Research UK;   Heptares Therapeutics Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2023 Category: Research Source Type: clinical trials